DỮ LIỆU BÁO CÁO THƯỜNG NIÊN
CÁC CÔNG TY NIÊM YẾT NƯỚC NGOÀI

Báo cáo thường niên năm 2022 của Reneo Pharmaceuticals

Reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. Many of these diseases are associated with deficits in cellular metabolism and energy production. Their goal is to improve daily function and quality of life of patients suffering from these diseases, most specifically, by improving how their mitochondria … More work, preserving muscle function and preventing muscle injury, weakness and wasting. They are currently advancing a novel molecule into several diseases. Their experienced team of drug development experts, who have collaborated in many successful programs, are dedicated and passionate about finding effective therapies for these complex rare diseases.

TÊN CÔNG TY / COMPANY
Reneo Pharmaceuticals

SÀN CHỨNG KHOÁN / STOCK EXCHANGE
NASDAQ (US)

MÃ CHỨNG KHOÁN / TICKER
RPHM

KỲ BÁO CÁO
2022

NGÀNH / INDUSTRY
Biotechnology

LĨNH VỰC / SECTOR
Healthcare

LƯU Ý

  • Xin vui lòng đợi một lát để Báo cáo được tải về, tùy thuộc vào dung lượng của Báo cáo mà thời gian có thể nhanh hoặc chậm.
  • Báo cáo chỉ cho phép xem từ Việt Nam.